```
=>
Uploading C:\Program Files\Stnexp\Queries\1132.str

L6      STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6                STR
```



we did species

```
Structure attributes must be viewed using STN Express query preparation.


=> s l6 sss sam
SAMPLE SEARCH INITIATED 15:10:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   4695 TO ITERATE

 21.3% PROCESSED    1000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       89792 TO    98008
PROJECTED ANSWERS:          73278 TO    80718

L7           50 SEA SSS SAM L6

=> s l6 sss full
FULL SEARCH INITIATED 15:10:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  93401 TO ITERATE

100.0% PROCESSED   93401 ITERATIONS                      76640 ANSWERS
SEARCH TIME: 00.00.01

L8        76640 SEA SSS FUL L6

=> file hcaplus
```

=> d l10 abs ibib kwic hitstr 60, 68, 74

L10 ANSWER 60 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB Title compds. I [E = bond, (substituted) amino, (alkyl)thio, (alkyl)sulfinyl, (alkyl)sulfonyl), CH(OH), O, CO, K = O, S, NH, (substituted)alkylamino, etc.; X = bond, CO, O, S, NH, etc.; R1 = HO2C, HO3S, C1-4 polyfluoroalkylsulfonylamino, H2NSO2, (HO)2P(O), (substituted)heterocyclyl, etc.; R2a, R2b = H, halo, H2N, O2N, C1-4 alkyl, C1-4 alkoxy, etc.; R3a = H, halo, C1-6 alkyl, C1-6 alkoxy, etc.; R3b = H, halo, O2N, C1-6 alkyl, hydroxy-C1-4-alkyl, etc.; R6 = C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl which can be substituted, R8 = H, HO, (alkyl)(dialkyl)amino, etc.; r = 1, 2] and their salts, as angiotensin II antagonists useful in treatment of hypertension, **ocular** hypertension, on certain CNS disorders (no data) are prepared 5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-yl)methyl]pyrazole (preparation given) in CCl4 was diazotized to give the pyrazole derivative which was heated with NaCN in DMSO to give the nitrilepyrazole which was diluted with brine and extracted with ether to give the title pyrazole II. Pharmaceutical formulations comprising II are given.

ACCESSION NUMBER: 1992:106284 HCAPLUS
DOCUMENT NUMBER: 116:106284
TITLE: Preparation of substituted pyrazoles, isoxazoles and isothiazoles as angiotensin II antagonists
INVENTOR(S): Allen, Eric E.; Greenlee, William J.; MacCoss, Malcolm; Ashton, Wallace T.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DELACROIX

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9115479	A1	19911017	WO 1991-US1952	19910327 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2079343	AA	19911001	CA 1991-2079343	19910327 <--
EP 523141	A1	19930120	EP 1991-907490	19910327 <--
R: CH, DE, FR, GB, IT, LI, NL				
JP 05505822	T2	19930826	JP 1991-507326	19910327 <--

PRIORITY APPLN. INFO.: US 1990-501469 19900330
WO 1991-US1952 19910327

OTHER SOURCE(S): MARPAT 116:106284

PI WO 9115479 A1 **19911017**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9115479	A1	19911017	WO 1991-US1952	19910327 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2079343	AA	19911001	CA 1991-2079343	19910327 <--
EP 523141	A1	19930120	EP 1991-907490	19910327 <--
R: CH, DE, FR, GB, IT, LI, NL				
JP 05505822	T2	19930826	JP 1991-507326	19910327 <--

AB . . . H, HO, (alkyl)(dialkyl)amino, etc.; r = 1, 2] and their salts, as angiotensin II antagonists useful in treatment of hypertension, **ocular** hypertension, on certain CNS disorders (no data) are prepared 5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-yl)methyl]pyrazole (preparation given) in CCl4 was diazotized to give the pyrazole. . .

IT **Glaucoma** (disease)
(treatment of, substituted pyrazoles, isothiazoles, and isoxazoles for)

IT 937-12-2P 1118-03-2P 70102-84-0P 70680-21-6P 114772-39-3P
114772-53-1P 120568-11-8P 124750-51-2P 124750-53-4P 138444-15-2P
138733-39-8P 138733-40-1P 138733-41-2P 138733-42-3P
138733-43-4P 138733-44-5P 138733-45-6P 138733-46-7P 138733-47-8P
138733-48-9P 138733-49-0P 138733-50-3P 138733-51-4P 138733-52-5P
138733-53-6P 138733-54-7P 138733-55-8P 138733-56-9P 138733-57-0P
138733-58-1P 138733-59-2P 138733-60-5P 138733-61-6P 138762-16-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of angiotensin II inhibitors)

IT 137645-69-3P 138531-94-9P **138717-60-9P** 138717-61-0P
138717-62-1P 138717-63-2P 138717-64-3P 138717-65-4P 138717-66-5P
138717-67-6P 138717-68-7P 138717-69-8P 138717-70-1P 138717-71-2P
138717-72-3P 138717-73-4P 138717-74-5P 138717-75-6P 138717-76-7P
138717-77-8P **138717-78-9P 138717-79-0P**
138717-80-3P 138717-81-4P 138717-82-5P
138717-83-6P 138717-84-7P 138717-85-8P
138717-86-9P 138717-87-0P 138717-88-1P
138717-89-2P 138717-90-5P 138717-91-6P
138717-92-7P 138717-93-8P 138717-94-9P
138717-95-0P 138717-96-1P 138717-97-2P
138717-98-3P 138717-99-4P 138718-00-0P
138718-01-1P 138718-02-2P 138718-03-3P
138718-04-4P 138718-05-5P 138732-48-6P 138732-49-7P 138732-50-0P
138732-51-1P 138732-52-2P 138732-53-3P 138732-54-4P 138732-55-5P
138732-56-6P 138732-57-7P 138732-58-8P 138732-59-9P 138732-60-2P
138732-61-3P 138732-62-4P 138732-63-5P 138732-64-6P 138732-65-7P
138732-66-8P 138732-67-9P 138732-68-0P 138732-69-1P 138732-70-4P

138732-71-5P 138732-72-6P 138732-73-7P 138732-74-8P 138732-75-9P
138732-76-0P 138732-77-1P 138732-78-2P 138732-79-3P 138732-80-6P
138732-81-7P 138732-82-8P 138732-83-9P 138732-84-0P 138732-85-1P
138732-86-2P 138732-87-3P 138732-88-4P 138732-89-5P 138732-90-8P
138732-91-9P 138732-92-0P 138732-93-1P 138732-94-2P 138732-95-3P
138732-96-4P 138732-97-5P 138732-98-6P 138732-99-7P 138733-00-3P
138733-01-4P 138733-02-5P 138733-03-6P 138733-04-7P 138733-05-8P
138733-06-9P 138733-07-0P 138733-08-1P 138733-09-2P 138733-10-5P
138733-11-6P 138733-12-7P 138733-13-8P 138733-14-9P 138733-15-0P
138733-16-1P 138733-17-2P 138733-18-3P 138733-19-4P 138733-20-7P
138733-21-8P 138733-22-9P 138733-23-0P 138733-24-1P 138733-25-2P
138733-26-3P 138733-27-4P 138733-28-5P 138733-29-6P 138733-30-9P
138733-31-0P 138733-32-1P 138733-33-2P 138733-34-3P 138733-35-4P
138733-36-5P 138733-37-6P 138733-38-7P 138762-09-1P 138762-10-4P
138762-11-5P 138762-12-6P 138762-13-7P 138762-14-8P 138762-15-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin II inhibitor)

IT **138733-39-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of angiotensin II inhibitors)

RN 138733-39-8 HCAPLUS
CN 5-Isoxazolamine, 3-butyl-4-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **138717-60-9P 138717-78-9P 138717-79-0P**
138717-80-3P 138717-81-4P 138717-82-5P
138717-83-6P 138717-84-7P 138717-85-8P
138717-86-9P 138717-87-0P 138717-88-1P
138717-89-2P 138717-90-5P 138717-91-6P
138717-92-7P 138717-93-8P 138717-94-9P
138717-95-0P 138717-96-1P 138717-97-2P
138717-98-3P 138717-99-4P 138718-00-0P
138718-01-1P 138718-02-2P 138718-03-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin II inhibitor)

RN 138717-60-9 HCAPLUS
CN 5-Isoxazolamine, 3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-78-9 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-79-0 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 4-[[2'-[(benzoylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-butyl- (9CI) (CA INDEX NAME)



RN 138717-80-3 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[(trifluoroacetyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-81-4 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-82-5 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[(cyclopropylcarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-83-6 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 4-[[2'-[[(diphenylacetyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)



RN 138717-84-7 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-85-8 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 4-[[2'-[[(cyclopropylcarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)



DELACROIX

RN 138717-86-9 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-propyl-4-[[2'-[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-87-0 HCAPLUS
CN 5-Isoxazolecarboxamide, 3-butyl-N-(phenylsulfonyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-88-1 HCAPLUS
CN Methanesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 138717-89-2 HCAPLUS
CN Ethanesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)

DELACROIX



RN 138717-90-5 HCAPLUS
CN Benzamide, N-[[4'-[[3-butyl-5-[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-91-6 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 4-[[2'-[(benzoylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)



RN 138717-92-7 HCAPLUS

DELACROIX

CN Cyclopropanecarboxamide, N-[[4'-[[3-butyl-5-[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-93-8 HCAPLUS
CN Methanesulfonamide, N-[3-butyl-4-[[2'-[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 138717-94-9 HCAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 138717-95-0 HCAPLUS
CN Ethanesulfonamide, 1,1,2,2,2-pentafluoro-N-[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 138717-96-1 HCAPLUS
CN Benzamide, N-[[4'-[[3-propyl-5-[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-97-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[[4'-[[3-propyl-5-[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10/038,113

SOURCE: U.S., 4 pp. Cont. of U.S. Ser. No. 18,330, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4888327	A	19891219	US 1988-228621	19880804 <--

PRIORITY APPLN. INFO.: US 1984-659352 19841010
US 1987-18330 19870224

PI US 4888327 A **19891219**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4888327	A	19891219	US 1988-228621	19880804 <--

AB Antibiotic synergistic compns. for topical administration contain an aminoglycoside, a benzylpyrimidine, and a sulfonamide. An **ophthalmic** ointment was prepared consisting of tobramycin 3, trimethoprim 3, sulfonamide 60, mineral oil 150, petrolatum base 200, and chlorobutanol 5. . .

ST antibiotic ointment **ophthalmic**

IT Sulfonamides
RL: BIOL (Biological study)
(**ophthalmic** formulations containing aminoglycoside antibiotics and benzylpyrimidines and)

IT Antibiotics
(aminoglycoside, **ophthalmic** formulations containing sulfonamides and benzylpyrimidines and)

IT Sulfonamides
RL: BIOL (Biological study)
(mixts., with tobramycin and trimethoprim, antibiotic synergistic **ophthalmic** formulations containing)

IT Pharmaceutical dosage forms
(solns., **ophthalmic**, aminoglycoside-benzylpyrimidine-sulfonamide mixts. in)

IT **127-69-5D**, mixture with benzylpyrimidine derivative and tobramycin
738-70-5D, mixts. with sulfonamides and tobramycin 32986-56-4D, mixts. with benzylpyrimidine derivs. and sulfonamides **126855-15-0**
RL: BIOL (Biological study)
(antibiotic synergistic **ophthalmic** formulation containing)

IT 106564-15-2D, derivs., mixts. with aminoglycoside antibiotics and sulfonamides
RL: BIOL (Biological study)
(**ophthalmic** formulations containing)

IT **127-69-5D**, mixture with benzylpyrimidine derivative and tobramycin
126855-15-0
RL: BIOL (Biological study)
(antibiotic synergistic **ophthalmic** formulation containing)

RN 127-69-5 HCAPLUS

CN Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)

10/038,113



RN 126855-15-0 HCAPLUS
CN D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→4)]-2-deoxy-, mixt. with 4-amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide and 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine (9CI) (CA INDEX NAME)

CM 1

CRN 32986-56-4
CMF C18 H37 N5 O9

Absolute stereochemistry.



CM 2

CRN 738-70-5
CMF C14 H18 N4 O3



DELACROIX

CM 3

CRN 723-46-6
CMF C10 H11 N3 O3 S



L10 ANSWER 74 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN
AB A buffered solution for the local treatment of eye infections contains neoxazol 4, diethanolamine 1.5-1.7, dextran 40,000 1-2, chlorhexidine acetate or diacetate 0.001-0.01, EDTA-Na2 0.05-0.1, NaCl 0.7-0.9, methylene blue 0.0025-0.005 and water to 100%.
ACCESSION NUMBER: 1988:62494 HCAPLUS
DOCUMENT NUMBER: 108:62494
TITLE: Neoxazol-containing **ophthalmic** solution
INVENTOR(S): Ban, Petra; Chereches, Silvia; Olteanu, Mircea; Banacu, Ioan
PATENT ASSIGNEE(S): Intreprinderea de Medicamente "Biofarm", Rom.
SOURCE: Rom., 2 pp.
CODEN: RUXXA3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 91196	B1	19870330	RO 1985-117579	19850208 <--

PRIORITY APPLN. INFO.: RO 1985-117579 19850208
TI Neoxazol-containing **ophthalmic** solution
PI RO 91196 B1 **19870330**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI RO 91196	B1	19870330	RO 1985-117579	19850208 <--

IT **127-69-5**, Neoxazol
RL: BIOL (Biological study)
(**ophthalmic** solution containing)
IT **127-69-5**, Neoxazol
RL: BIOL (Biological study)
(**ophthalmic** solution containing)
RN 127-69-5 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)

10/038,113



DELACROIX

```
=> s l8 and (glaucom? or ocular? or intra(2a)intraocular? or ophthal?)
         28367 L8
          5488 GLAUCOM?
         13724 OCULAR?
         43439 INTRA
          7174 INTRAOCULAR?
             4 INTRA(2A)INTRAOCULAR?
         11359 OPHTHAL?
L9         208 L8 AND (GLAUCOM? OR OCULAR? OR INTRA(2A)INTRAOCULAR? OR OPHTHAL
               ?)

=> s l9 and py<=2000
      20616029 PY<=2000
L10         98 L9 AND PY<=2000

=> d l10 ibib 1-98
```

10/038,113

```
=> d his

     (FILE 'HOME' ENTERED AT 15:06:56 ON 23 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 15:07:15 ON 23 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1 SSS SAM
L3              8 S L1 SSS FULL

     FILE 'HCAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT
     15:08:15 ON 23 JUN 2004

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 15:08:42 ON 23 JUN 2004
L4              6 S L3
L5              6 DUP REM L4 (0 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 15:09:21 ON 23 JUN 2004

     FILE 'REGISTRY' ENTERED AT 15:10:01 ON 23 JUN 2004
L6                STRUCTURE UPLOADED
L7             50 S L6 SSS SAM
L8          76640 S L6 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 15:10:37 ON 23 JUN 2004
L9            208 S L8 AND (GLAUCOM? OR OCULAR? OR INTRA(2A)INTRAOCULAR? OR OPHT
L10            98 S L9 AND PY<=2000

     FILE 'STNGUIDE' ENTERED AT 15:12:14 ON 23 JUN 2004

     FILE 'HCAPLUS' ENTERED AT 15:14:30 ON 23 JUN 2004

     FILE 'STNGUIDE' ENTERED AT 15:15:23 ON 23 JUN 2004
```



RN 138717-98-3 HCAPLUS
CN 1H-Tetrazole, 5-[4'-[[3-butyl-5-[[(4-chlorophenyl)methyl]sulfinyl]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 138717-99-4 HCAPLUS
CN Benzoic acid, 2-[[[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 138718-00-0 HCAPLUS
CN 5-Isoxazolecarboxamide, 3-butyl-N-[(1-methylethyl)sulfonyl]-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138718-01-1 HCAPLUS
CN 5-Isoxazolecarboxamide, 3-butyl-N-(cyclopropylsulfonyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138718-02-2 HCAPLUS
CN Benzenesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 138718-03-3 HCAPLUS
CN 3-Pyridinesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 68 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN
AB Antibiotic synergistic compns. for topical administration contain an aminoglycoside, a benzylpyrimidine, and a sulfonamide. An **ophthalmic** ointment was prepared consisting of tobramycin 3, trimethoprim 3, sulfonamide 60, mineral oil 150, petrolatum base 200, and chlorobutanol 5 mg/g.

ACCESSION NUMBER: 1990:204729 HCAPLUS
DOCUMENT NUMBER: 112:204729
TITLE: Topical antibiotic compositions
INVENTOR(S): Edwards, John G.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

DELACROIX